Tatyana A Grushko
Overview
Explore the profile of Tatyana A Grushko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
486
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hardeman A, Han Y, Grushko T, Mueller J, Gomez M, Zheng Y, et al.
PLoS One
. 2022 Jun;
17(6):e0268693.
PMID: 35749404
Maternal embryonic leucine-zipper kinase (MELK) regulates cell cycle progression and is highly expressed in many cancers. The molecular mechanism of MELK dysregulation has not been determined in aggressive forms of...
2.
Grushko T, Filiaci V, Montag A, Apushkin M, Gomez M, Monovich L, et al.
Appl Immunohistochem Mol Morphol
. 2021 Jul;
30(1):27-35.
PMID: 34224438
We performed a pilot study in anticipation of using long-aged precut formalin-fixed paraffin-embedded tissue sections stored in real-world conditions for translational biomarker studies of topoisomerase 2A (TOP2A), Ki67, and human...
3.
Ezewuiro O, Grushko T, Kocherginsky M, Habis M, Hurteau J, Mills K, et al.
PLoS One
. 2016 Jan;
11(1):e0147145.
PMID: 26788855
There is increasing evidence that metformin, a commonly used treatment for diabetes, might have the potential to be repurposed as an economical and safe cancer therapeutic. The aim of this...
4.
Young N, Soneru C, Liu J, Grushko T, Hardeman A, Olopade O, et al.
Target Oncol
. 2015 Jan;
10(4):501-8.
PMID: 25559287
Epidermal growth factor receptor (EGFR) inhibitors have demonstrated efficacy in squamous cell carcinoma of the head and neck (SCCHN). In addition to EGFR, other ErbB family members are expressed and...
5.
Perez C, Song H, Raez L, Agulnik M, Grushko T, Dekker A, et al.
Oral Oncol
. 2012 Apr;
48(9):887-92.
PMID: 22513208
Background: Gefitinib has activity in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) and skin toxicity has been postulated to be a predictor of response and...
6.
Catenacci D, Cervantes G, Yala S, Nelson E, El-Hashani E, Kanteti R, et al.
Cancer Biol Ther
. 2011 May;
12(1):9-46.
PMID: 21543897
RON (MST1R) is one of two members of the MET receptor tyrosine kinase family, along with parent receptor MET. RON has a putative role in several cancers, but its expression...
7.
Cohen E, Haraf D, Kunnavakkam R, Stenson K, Blair E, Brockstein B, et al.
J Clin Oncol
. 2010 May;
28(20):3336-43.
PMID: 20498391
Purpose: Assess efficacy and toxicity of gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, added to, and in maintenance after, concurrent chemoradiotherapy (CCRT) in locally advanced head and neck cancer...
8.
Burness M, Grushko T, Olopade O
Cancer J
. 2010 Feb;
16(1):23-32.
PMID: 20164687
Triple-negative breast cancers represent a subset of breast cancers with a particularly aggressive phenotype and poor clinical outcomes. Recent molecular profiling of these tumors has revealed a high frequency of...
9.
Olopade O, Grushko T, Nanda R, Huo D
Clin Cancer Res
. 2008 Dec;
14(24):7988-99.
PMID: 19088015
Breast cancer is a complex disease caused by the progressive accumulation of multiple gene mutations combined with epigenetic dysregulation of critical genes and protein pathways. There is substantial interindividual variability...
10.
Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, et al.
Breast Cancer Res Treat
. 2007 Oct;
111(1):113-20.
PMID: 17932744
Estrogen receptor alpha (ER) and its ligand estrogen play vital roles in the development, progression and treatment of breast cancer. An increasing number of studies have also provided evidence linking...